Zobrazeno 1 - 10
of 320
pro vyhledávání: '"Shi-ming Lin"'
Autor:
Po-Ting Lin, Wei Teng, Wen-Juei Jeng, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen
Publikováno v:
Journal of the Formosan Medical Association, Vol 123, Iss 7, Pp 788-795 (2024)
Background: Locoregional therapy and multi-kinase inhibitor agent have been the backbone of treatment for hepatocellular carcinoma (HCC) patients. However, the effect of combination or sequential use of locoregional therapy on HCC patients receiving
Externí odkaz:
https://doaj.org/article/dd0e84d5046f46e492a2131ecc45a421
Autor:
Po‐Ting Lin, Min‐Hua Hung, Shih‐Chieh Shao, Hui‐Yu Chen, Yuk‐Ying Chan, Kai‐Cheng Chang, Shi‐Ming Lin, Huang‐Tz Ou
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 14902-14911 (2023)
Abstract Purpose The aim of this study was to investigate the factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment. Methods We conducted a retrospective study using a multi‐institution
Externí odkaz:
https://doaj.org/article/c5a9cab3ae0b43b88340a7bf83c1bc8e
Autor:
Tsung-Hao Liu, San-Chi Chen, Kun-Ming Rau, Li-Chun Lu, Po-Ting Lin, Yung-Yeh Su, Wei Teng, Shiue-Wei Lai, Ren-Hua Yeh, Tsui-Mai Kao, Pei-Chang Lee, Chi-Jung Wu, Chien-Hung Chen, Chih-Hung Hsu, Shi-Ming Lin, Yi-Hsiang Huang, Li-Tzong Chen, Ann-Lii Cheng, Ying-Chun Shen
Publikováno v:
Liver Cancer (2024)
Introduction The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized. Methods Patients with advanced HCC who received
Externí odkaz:
https://doaj.org/article/982567d91e37462383001cc9dc3d4719
Autor:
Chung‐Wei Su, Wei Teng, Po‐Ting Lin, Wen‐Juei Jeng, Kuei‐An Chen, Yi‐Chung Hsieh, Wei‐Ting Chen, Ming‐Mo Ho, Chia‐Hsun Hsieh, Ching‐Ting Wang, Pei‐Mei Chai, Chen‐Chun Lin, Chun‐Yen Lin, Shi‐Ming Lin
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 7077-7089 (2023)
Abstract Background Lenvatinib and atezolizumab plus bevacizumab(A + B) have been used for unresectable hepatocellular carcinoma (HCC) as first‐line therapy. Real‐world studies comparison of efficacy and safety in these two regimens are limited,
Externí odkaz:
https://doaj.org/article/216f93a49f9b419c95928f65f96fe04e
Autor:
Wei Teng, Wen‐Juei Jeng, Wei‐Ting Chen, Chen‐Chun Lin, Chun‐Yen Lin, Shi‐Ming Lin, I‐Shyan Sheen
Publikováno v:
Cancer Medicine, Vol 11, Iss 20, Pp 3786-3795 (2022)
Abstract Background A soluble form of cytotoxic‐T‐lymphocyte‐antigen‐4 (sCTLA‐4) is a prognostic biomarker for several cancers but remains unclear in HCC patients. The aim of study is to evaluate the predictive role of serum sCTLA‐4 level
Externí odkaz:
https://doaj.org/article/737e1a030570431f8bc922e7b11ddd63
Publikováno v:
Liver Cancer, Pp 1-1 (2024)
Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan established HCC management consensus guidelines in 2016 and updated them in 2
Externí odkaz:
https://doaj.org/article/2e1bf5c562ff42bc85be4017de1bc357
Publikováno v:
Liver Cancer, Pp 1-19 (2022)
Background: Multikinase inhibitors (MKIs) have been shown to improve survival in patients with hepatocellular carcinoma (HCC) compared with placebo. Distinct from other MKIs, cabozantinib has inhibitory activity for both AXL and MET. This review cons
Externí odkaz:
https://doaj.org/article/ef1eb659b91a462dbe1ec41384926187
Autor:
Thomas Yau, David Tai, Stephen Lam Chan, Yi-Hsiang Huang, Su Pin Choo, Chiun Hsu, Tan To Cheung, Shi-Ming Lin, Wei Peng Yong, Joycelyn Lee, Thomas Leung, Tracy Shum, Cynthia S. Y. Yeung, Anna Yin-Ping Tai, Ada Lai Yau Law, Ann-Lii Cheng, Li-Tzong Chen
Publikováno v:
Liver Cancer (2022)
Background: Asia has a high burden of hepatocellular carcinoma (HCC) due to the high rates of chronic hepatitis B infection, and accounts for 70% of HCC cases globally. In the past 20 years, the systemic treatment landscape of advanced HCC has evolve
Externí odkaz:
https://doaj.org/article/40f6cf6d91f4490ba3706de915130645
Autor:
Yu-Yun Shao, Shen-Yung Wang, Shi-Ming Lin, Kuan-Yang Chen, Jeng-Hwei Tseng, Ming-Chih Ho, Rheun-Chuan Lee, Po-Chin Liang, Li-Ying Liao, Kai-Wen Huang, Jui-Ting Hu, Ja-Der Liang, Kwong-Ming Kee, Chih-Lin Lin, Chung-Kwe Wang, Sheng-Nan Lu, Jing-Houng Wang, Wei-Chen Lee, Chien-Hung Chen, Chun-Jen Liu, Yi-Hsiang Huang, Chia-Chi Wang, Tsang-En Wang, Po-Heng Chuang, Chia-Yen Dai, Chiun Hsu, San-Chi Chen, Chia-Hsun Hsieh
Publikováno v:
Journal of the Formosan Medical Association, Vol 120, Iss 4, Pp 1051-1060 (2021)
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommend
Externí odkaz:
https://doaj.org/article/602033b060fa4a748f841fd37bd8fefc
Autor:
Xian Pan, Han-Lu Wang, Shi-Ming Lin, Jia-Li Lin, Dan-Dan Ruan, Jian-Hui Zhang, Ting Chen, Jie-Wei Luo, Zhu-Ting Fang
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Extraskeletal osteosarcoma is a rare malignant soft-tissue sarcoma that is difficult to diagnose. Surgery is a common treatment, although chemotherapy and radiotherapy are also used. Patients at risk of bleeding can undergo embolization combined with
Externí odkaz:
https://doaj.org/article/e2b17e0dd439420caaacd5b765afe28f